StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research report sent to investors on Friday. The firm issued a hold rating on the stock. Separately, Mizuho restated a neutral rating and issued a $3.50 price target on shares of Corvus Pharmaceuticals in a report on Thursday, March 30th. Corvus […]
StockNews.com began coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research note issued to investors on Thursday. The firm issued a sell rating on the stock. Separately, Mizuho reaffirmed a neutral rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research report on Thursday, March 30th. […]
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 238,700 shares, a growth of 50.8% from the March 31st total of 158,300 shares. Based on an average daily volume of 215,100 shares, the days-to-cover ratio is […]
Research analysts at StockNews.com started coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a report released on Thursday. The firm set a “sell” rating on the stock. Separately, Mizuho reissued a “neutral” rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research report on Thursday, March 30th. […]
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 238,700 shares, a growth of 50.8% from the March 31st total of 158,300 shares. Based on an average daily volume of 215,100 shares, the […]